Global private-equity (PE) activity saw its steepest contraction since Q3 2020 in Q2 2025, with deal count down 17% Q/Q to 3,769 and capital deployed falling 28% to $363.7M. Average ticket size dropped 22% to $285M as sponsors shifted from large buyouts to smaller, more disciplined transactions. Even so, volumes remain above pre-pandemic norms, marking a fifth consecutive quarter above 3,500 deals. The Americas remained dominant, delivering 59% of global PE capital ($214B) and 47% of deals (1,771), led by the U.S. at $202B. However, U.S. investment fell sharply from Q1’s $264.5B amid high borrowing costs, geopolitical risk, and tariff uncertainty. Mega-deals persisted in energy, infrastructure, and AI-linked assets such as Blackstone’s $11.5B TXNM Energy buyout and Brookfield’s $9.9B AI data-center project while automotive activity collapsed on supply-chain and tariff headwinds.

Europe generated $117.4B from 1,669 deals, with the UK a bright spot as capital rose to $36.8B on middle-market resilience. Still, exits weakened sharply; UK H1 exit value dropped to $16.1B from $51.8B in 2024, with IPO activity near zero, prompting reliance on continuation vehicles. Asia-Pacific performance diverged China hit a decade-low $700M, Japan fell to $3.6B, but Australia doubled to $11.2B on large-cap deals. Tight financing conditions pushed sponsors toward higher-equity, lower-leverage deals, compressing IRRs and widening valuation gaps. Secondary buyouts rose 12.5% Q/Q, while fundraising fell 34% to $224.9B as LPs pressed for liquidity and scrutinized governance. Evergreen funds and continuation vehicles gained traction, especially in long-duration sectors like defense tech and infrastructure. Q3 2025 outlook hinges on U.S.–China tariff resolution, U.S. fiscal reforms, and IPO market recovery. Investors should target high-quality, domestic-oriented assets in AI infrastructure, healthcare, and renewables, with disciplined valuations and robust exit strategies in an elevated-risk environment.

Arrow Previous Whitepaper

Tariffs, Trade Wars, and the Risk to Drug Access

Next Whitepaper Arrow

AI - Driven Consolidation Will Re-Energize Global M&A

Download Whitepaper

Let’s build a scalable, future-ready research and analytics capability together.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Build a Scalable, Finance-Led Research Capability

Partner with RCK Analytics to access finance-led teams delivering research and analytics at institutional standards, with speed, scale, and cost efficiency.
generic-cta-img
Loading...